Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Wesana Health.

    Client Virtual Booth

    WESANA HEALTH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Wesana Health
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Chicago, IL
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://wesanahealth.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/wesana/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

    Details:

    Through the acquisition, Lucy adds Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.


    Lead Product(s): Psilocybine,Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Lucy Scientific Discovery

    Deal Size: $0.5 million Upfront Cash: $0.4 million

    Deal Type: Acquisition July 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health

    Details:

    Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.


    Lead Product(s): Psilocybine,Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Lucy Scientific Discovery

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition March 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant

    Details:

    Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone.


    Lead Product(s): Psilocybine,Imipramine

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

    Details:

    The Company received positive written responses from the FDA, outlining the requirements to open the IND and commence with clinical studies for SANA-013,for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder.


    Lead Product(s): Psilocybine,Cannabidiol

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: SANA-013

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 14, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search